Search for a cure for chronic hepatitis B infection: How close are we?

doi:10.4254/wjh.v7.i9.1272

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11077)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

580

WORD

285

HTML

5699

Figures (1-1)

183

Tables (1-1)

172

Sum=6919

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

598

Download

1244

Sum=1842

Publishing Process of This Article

Item

Count

Browse

935

Download

1381

Sum=2316

May 28, 2015 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. May 28, 2015; 7(9): 1272-1281
Published online May 28, 2015. doi: 10.4254/wjh.v7.i9.1272

Table 1 Novel anti-hepatitis B virus compounds in development

Therapeutic agents	Mechanism	Manufacturer	Status
Viral entry inhibitors
Myrcludex B	Entry inhibition	Myr_GmbH, Germany	Phase IIA, Russia
cccDNA Transcription inhibitors
CC-0975, CC-0346 (DSS)	Induces deproteinization of rcDNA		Preclinical
LTβR	Induces cccDNA cytidine deamination		Preclinical
Small molecules	cccDNA transcription inhibitor		Preclinical
DNA editing technology
ZFNs	cccDNA inactivation		Preclinical
TALENs	cccDNA inactivation		Preclinical
RNAi gene silencer
ARC 520	RNAi gene silencer	Arrowhead Research Pasadena, CA	Phase IIA
New nucleoside analogues
Besifovir (LB80380)	Inhibits viral DNA polymerase	LG Life Sciences, South Korea	Phase II
MIV-210	Inhibits viral DNA polymerase	Medivir/Daewoong, South Korea	Phase II
Tenofovir alafenamide (GS-7340)	Prodrug of tenofovir	Gilead Foster City, CA	Phase III
Interruption of HBV capsid assembly
Heteroaryldihydropyrimidine (Bay 41-4109)	Inhibits viral nucleocapsid	AiCuris, Germany	PhaseI
Heteroaryldihydropyrimidine (HAP12)	Inhibits capsid assembly		Preclinical
NVR-1221	Capsid inhibitor	Novira Therapeutics, Doylestown, PA	Phase IA
HBsAg release inhibitor
REP 9AC	HBsAg release inhibitor	REPLICor Inc. Montreal, Quebec	Phase I
HBsAg-3 shRNA	HBsAg expression inhibitor		Preclinical
Immunomodulator
GS-9620	TLR-7 agonist	Gilead Foster City, United States	Phase I
CYT 107 (interleukin-7)	Immunomodulator	Cytheris, Paris, France	Phase I/IIA
Therapeutic vaccination
GS-4774	HBV X, surface and core antigens	Gilead Sciences with Globe Immune Louisville, CO	Phase II
DV601	HBV surface and core antigens	Dynavax, Berkeley, CA	Phase IB
NASVAC	HBV surface and core antigens	CIGB, Cuba	Phase I
HBV core Ag vaccine	T-cell mediated therapeutic vaccine	Emergent Europe, United Kingdom	Phase I

Modified from hepatitis b foundation drug watch[70]. NASVAC: Nasal Vaccine Candidate; rcDNA: Relaxed circular DNA; RNAi: RNA interference; shRNA: Short/small hairpin RNA; cccDNA: Covalently closed circular DNA; DSS: Distributed sulphonamide; LTβR: LymphoToxin beta receptor; TALEN: Transcription activator-like effector nuclease; ZFN: Zinc finger nuclease; HBsAg: Hepatitis B virus antigen; HBV: Hepatitis B virus; TLR-7: Toll-like receptor-7.

Citation: Phyo WW, Soh AYS, Lim SG, Lee GH. Search for a cure for chronic hepatitis B infection: How close are we? World J Hepatol 2015; 7(9): 1272-1281
URL: https://www.wjgnet.com/1948-5182/full/v7/i9/1272.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i9.1272